The antiviral JNJ-A07 significantly reduces dengue virus transmission by Aedes aegypti mosquitoes when delivered via blood-feeding
Science Advances · 29.11.2024 · 10 (48)
DOI: 10.1126/sciadv.adr8338 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 29.11.2024. Verfasst von Ana L Rosales-Rosas und 10 weiteren Autor:innen. Beteiligte Einrichtung: KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virus-Host Interactions & Therapeutic App…. Hauptthemen laut MEDLINE: Aedes, Dengue Virus, Antiviral Agents, Dengue. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Dengue virus (DENV) is the most widespread mosquito-borne virus worldwide, but no antiviral therapies are available yet. The pan-serotype DENV inhibitor JNJ-A07 has shown potent activity in a mouse model. It remains unknown whether an antiviral drug ingested by mosquitoes could inhibit virus replication and thus reduce transmission to other hosts. Here, we investigated the antiviral activity of JNJ-A07 when administered in the blood meal to Aedes aegypti mosquitoes. JNJ-A07 blocked DENV-2 transmission by the mosquitoes in both pre-exposure and post-exposure settings. In addition, JNJ-A07 remained in the mosquito bodies for 7 days after blood meal. Reductions of DENV systemic infection in the mosquitoes suggested a potential for decreased proportions of DENV outbreaks in a simulated environment when the mosquitoes ingested JNJ-A07 via the blood meal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virus-Host Interactions & Therapeutic Approaches (VITA) Research Group, 3000 Leuven, Belgium.
- KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virology, Antiviral Drug & Vaccine Research Group, 3000 Leuven, Belgium.
- Janssen R&D, Titusville, NJ, USA.
- Janssen Global Public Health, Janssen Pharmaceutica NV, Beerse, Belgium.
- Janssen R&D, Beerse, Belgium.
ORCID-Profile: Ana L Rosales-Rosas, Winston Chiu, Atreyee Majumder, Alina Soto, Serge Masyn, Bart Stoops, Lanjiao Wang, Suzanne J F Kaptein, Olivia Goethals, Leen Delang
Zitieren
APA
Rosales-Rosas, A. L., Goossens, S., Chiu, W., Majumder, A., Soto, A., Masyn, S., Stoops, B., Wang, L., Kaptein, S. J. F., Goethals, O., & Delang, L. (2024). The antiviral JNJ-A07 significantly reduces dengue virus transmission by Aedes aegypti mosquitoes when delivered via blood-feeding. Science Advances, 10(48). https://doi.org/10.1126/sciadv.adr8338
Vancouver
Rosales-Rosas AL, Goossens S, Chiu W, Majumder A, Soto A, Masyn S, et al. The antiviral JNJ-A07 significantly reduces dengue virus transmission by Aedes aegypti mosquitoes when delivered via blood-feeding. Science Advances. 2024;10(48). doi:10.1126/sciadv.adr8338
BibTeX
@article{RosalesRosas2024,
author = {Rosales-Rosas, Ana L and Goossens, Sara and Chiu, Winston and Majumder, Atreyee and Soto, Alina and Masyn, Serge and Stoops, Bart and Wang, Lanjiao and Kaptein, Suzanne J F and Goethals, Olivia and Delang, Leen},
title = {The antiviral JNJ-A07 significantly reduces dengue virus transmission by Aedes aegypti mosquitoes when delivered via blood-feeding},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {48},
doi = {10.1126/sciadv.adr8338}
}
EUVIMED